With regard to the sector of activity in which this company is active, you will of course have to be interested in the research currently carried out by this one with the various phases of tests and clinical trials until the marketing authorizations are obtained.
A part of the capital of Editas Medicine is owned by large private or institutional investors, including ARK Investment Management with 9.23% of the shares, the Vanguard Group with 9.15%, Nikko Asset Management Americas with 6.24%, SSgA Funds Management with 3.71%, Polaris Growth Management with 2.63%, Flagship Pioneering with 2.45%, BlackRock Fund Advisors with 2.43%, Nikko Asset Management Co. with 2.22%, CaaS Capital Management with 2.05% and Capital Research Management with 1.90%.